An isotope dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS)-based candidate reference measurement procedure (RMP) for the quantification of methotrexate in human serum and plasma

被引:7
作者
Engel, Anett [1 ]
Ruhe, Lena [1 ]
Singh, Neeraj [2 ]
Wright, Jo Anne [2 ]
Liesch, Franziska [2 ]
Bauland, Friederike [3 ]
Ostermann, Annika I. I. [1 ]
Sumalowitsch, Tamara [1 ]
Schweinsberg, Vincent J. T. [4 ]
Geistanger, Andrea [2 ]
Hegel, Johannes Kolja [1 ]
Geletneky, Christian [2 ]
Taibon, Judith [2 ,5 ]
机构
[1] Lab Berlin Charite Vivantes Serv GmbH, Collaborat & Innovat Management, Dept Studies, Berlin, Germany
[2] Roche Diagnost GmbH, Berlin, Germany
[3] Chrestos Concept GmbH & Co KG, Essen, Germany
[4] Lab Berlin Charite Vivantes GmbH, Dept Lab Med & Toxicol, Berlin, Germany
[5] Roche Diagnost GmbH, Nonnenwald 2, D-82377 Penzberg, Germany
关键词
isotope dilution LC-MS/MS; methotrexate; qNMR; reference measurement procedure; SI units; traceability; LC-MS/MS ASSAY; PHARMACOKINETICS; VALIDATION; METABOLITE; CHILDREN;
D O I
10.1515/cclm-2022-1001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: To develop an isotope dilution-liquid chromatography-tandem mass spectrometry-(ID-LC-MS/MS)-based candidate reference measurement procedure (RMP) for quantification of methotrexate in human serum and plasma.Methods: Quantitative nuclear magnetic resonance (qNMR) was used to determine absolute methotrexate content in the standard. Separation was achieved on a biphenyl reversed phase analytical column with mobile phases based on water and acetonitrile, both containing 0.1% formic acid. Sample preparation included protein precipitation in combination with high sample dilution, and method validation according to current guidelines. The following were assessed: selectivity (using analyte-spiked samples, and relevant structural-related compounds and interferences); specificity and matrix effects (via post-column infusion and comparison of human matrix vs. neat samples); precision and accuracy (in a five-day validation analysis). RMP results were compared between two independent laboratories. Measurement uncertainty was evaluated according to current guidelines.Results: The RMP separated methotrexate from potentially interfering compounds and enabled measurement over a calibration range of 7.200-5,700 ng/mL (0.01584-12.54 mu mol/L), with no evidence of matrix effects. All pre-defined acceptance criteria were met; intermediate precision was <= 4.3% and repeatability 1.5-2.1% for all analyte concentrations. Bias was -3.0 to 2.1% for samples within the measuring range and 0.8-4. 5% for diluted samples, independent of the sample matrix. RMP results equivalence was demonstrated between two independent laboratories (Pearson correlation coefficient 0.997). Expanded measurement uncertainty of target value-assigned samples was <= 3.4%.Conclusions: This ID-LC-MS/MS-based approach provides a candidate RMP for methotrexate quantification. Traceability of methotrexate standard and the LC-MS/MS platform were assured by qNMR assessment and extensive method validation.
引用
收藏
页码:1917 / 1929
页数:13
相关论文
共 42 条
[1]   Liquid chromatography tandem mass spectrometry in the clinical laboratory [J].
Adaway, Joanne E. ;
Keevil, Brian G. ;
Owen, Laura J. .
ANNALS OF CLINICAL BIOCHEMISTRY, 2015, 52 (01) :18-38
[2]   Development and validation of LC-MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism [J].
Al-Ghobashy, Medhat A. ;
Hassan, Said A. ;
Abdelaziz, Doaa H. ;
Elhosseiny, Noha M. ;
Sabry, Nirmeen A. ;
Attia, Ahmed S. ;
El-Sayed, Manal H. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2016, 1038 :88-94
[3]  
Armbruster David, 2007, Clin Biochem Rev, V28, P105
[4]   Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate [J].
Barreto, Jason N. ;
Peterson, Kristen T. ;
Barreto, Erin F. ;
Mara, Kristin C. ;
Dierkhising, Ross A. ;
Leung, Nelson ;
Witzig, Thomas E. ;
Thompson, Carrie A. .
SUPPORTIVE CARE IN CANCER, 2021, 29 (09) :5293-5301
[5]  
Beastall Graham H, 2018, EJIFCC, V29, P242
[6]   A fast LC-MS/MS assay for methotrexate monitoring in plasma: validation, comparison to FPIA and application in the setting of carboxypeptidase therapy [J].
Bouquie, Regis ;
Deslandes, Guillaume ;
Bernaldez, Blanca Nieto ;
Renaud, Christian ;
Dailly, Eric ;
Jolliet, Pascale .
ANALYTICAL METHODS, 2014, 6 (01) :178-186
[7]   The role of External Quality Assessment Schemes in Monitoring and Improving the Standardization Process [J].
Ceriotti, Ferruccio .
CLINICA CHIMICA ACTA, 2014, 432 :77-81
[8]   High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma [J].
Crews, KR ;
Liu, T ;
Rodriguez-Galindo, C ;
Tan, M ;
Meyer, WH ;
Panetta, JC ;
Link, MP ;
Daw, NC .
CANCER, 2004, 100 (08) :1724-1733
[9]   A U-HPLC-ESI-MS/MS-Based Stable Isotope Dilution Method for the Detection and Quantitation of Methotrexate in Plasma [J].
den Boer, Ethan ;
Heil, Sandra G. ;
van Zelst, Bertrand D. ;
Meesters, Roland J. W. ;
Koch, Birgit C. P. ;
te Winkel, Mariel L. ;
van den Heuvel-Eibrink, Marry M. ;
Luider, Theo M. ;
de Jonge, Robert .
THERAPEUTIC DRUG MONITORING, 2012, 34 (04) :432-439
[10]   Comparison of four immunoassays to an HPLC method for the therapeutic drug monitoring of methotrexate: Influence of the hydroxylated metabolite levels and impact on clinical threshold [J].
Descoeur, Juliette ;
Dupuy, Anne-Marie ;
Bargnoux, Anne-Sophie ;
Cristol, Jean-Paul ;
Mathieu, Olivier .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) :55-63